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Nonsteroidal anti-inflammatory drugs (NSAIDs) have
been used for relieving the inflammation caused by
various physiologic or pathologic conditions for more
than 100 years. An early clinical study demonstrated
that NSAIDs may attenuate cancer progression in
patients with familial adenomatous polyposis and
Gardner’s syndrome [1]. A benefit of NSAID use in re-
ducing cancer risk is supported by a large, population-
based epidemiologic investigation which concluded
that low-dose and regular use of NSAIDs reduced the
risk of fetal colon cancer [2]. Subsequent studies also
suggested that NSAIDs are effective in the prevention
of tumorigenesis of human cancers including lung,
breast, prostate, and esophagus [3–6].
The main target of NSAIDs was first described by
Sir John Vane in 1971 [7]. He reported that many
NSAIDs inhibited the enzymatic activity of prosta-
glandin G/H synthase (also named cyclooxygenase).
Cyclooxygenases (COXs) are the rate-limiting enzymes
that catalyze the conversion of arachidonic acid to
prostaglandins (PGs). Two COX isoforms with dis-
tinct tissue distributions and physiologic functions
have been identified in mammalian cells [8,9]. COX-1
is constitutively expressed in many tissues and plays
an important role in the control of homeostasis [10].
Conversely, COX-2 is an inducible enzyme and is
activated in response to extracellular stimuli such as
growth factors and proinflammatory cytokines [11].
In 1994, Eberhart et al showed that COX-2, but not
COX-1, is selectively upregulated in colorectal can-
cers [12]. Subsequent investigations indicated that
overexpression of COX-2 is frequently found in many
cancers including colon, lung, breast, pancreas, and
head and neck cancers [13–17], and is usually associ-
ated with poor prognosis and short survival.
Received: Aug 20, 2008 Accepted: Aug 30, 2008
Address correspondence and reprint requests to:
Dr Wen-Chun Hung, Institute of Biomedical
Sciences, National Sun Yat-Sen University,
Kaohsiung 804, Taiwan.
E-mail: hung1228@ms10.hinet.net
ANTI-METASTATIC ACTION OF NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS
Wen-Chun Hung
Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Epidemiological studies suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the
incidence and mortality of several types of human cancer. However, the molecular mechanisms
by which NSAIDs exert their chemopreventive and anticancer effects are not fully understood.
Cyclooxygenase 1 (COX-1) and COX-2 are the main targets for NSAIDs. Recent studies demon-
strate that COX-2 is overexpressed in many human cancers and may promote tumorigenesis via:
(1) stimulation of cancer cell proliferation; (2) increase of tumor angiogenesis; (3) prevention of
cancer cell apoptosis; (4) modulation of immunoregulatory reactions; and (5) enhancement of
tumor metastasis. NSAIDs may target the signaling molecules (from upstream activators to down-
stream effectors) involved in these mechanisms to attenuate the development and progression of
cancer. In this review, we discuss the recent findings with regard to the mechanisms by which
NSAIDs inhibit tumorigenesis and will specifically focus on the elucidation of NSAID-induced
inhibition of tumor metastasis.
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The contribution of COX-2 to tumorigenesis has
been intensively studied. Several mechanisms are con-
sidered to mediate the tumorigenic activity of COX-2.
First, PGs, the metabolites of COX-2, are growth pro-
moters and may directly stimulate proliferation of
cancer cells [18,19]. Second, COX-2 is an angiogenic
stimulator and has been shown to increase the produc-
tion of angiogenic factors and migration of endothe-
lial cells [20,21]. Third, COX-2-derived PGs function
as antiapoptotic molecules that may prevent apoptosis
induced by anticancer drugs [22,23]. Fourth, PGs are
immunoregulatory molecules and have been found
to suppress the antitumor activity of natural killer
cells and macrophages [24]. Finally, COX-2 expression
may increase the invasive ability of tumor cells to
promote cancer metastasis [25,26].
ANTI-CANCER EFFECTS OF NSAIDS
As aforementioned, COX-2 and PGs contribute to the
development of tumors via multiple mechanisms. It
seems reasonable that NSAIDs may target the signal-
ing molecules involved in these mechanisms to inhibit
tumorigenesis. A number of excellent reviews have
discussed the anticancer effects of NSAIDs in detail
[27–30]. So, I will briefly summarize the molecular
mechanisms underlying NSAID-induced tumor inhibi-
tion below and focus specifically on the antimetastatic
action of NSAIDs.
Suppression of proliferation via inhibition
of cell cycle progression
NSAIDs have been shown to repress the expression or
activity of cell cycle promoters. For example, expres-
sions of cyclin D1, A, and B and the enzymatic activi-
ties of cyclin E/cyclin-dependent kinase 2 (CDK2) and
cyclin B1/CDK1 are inhibited by NSAIDs [31–34].
These inhibitions lead to growth arrest in vitro and
tumor regression in vivo. In addition to inhibition of
cell cycle promoters, NSAIDs may also suppress cell
proliferation by upregulating negative cell cycle con-
trollers like p21Waf1 and p27Kip1 [31,35].
Induction of apoptotic cell death
The effect of NSAIDs on cell viability is drug- and
cell type-dependent. For example, we find that the
COX-2-selective inhibitor NS398 does not induce apo-
ptosis in lung cancer cells [36]. Similarly, the NSAID
rofecoxib exhibits little cytotoxic activity in vitro [37].
Conversely, the COX-2 inhibitor celecoxib effectively
causes apoptosis in colon cancer, cholangiocarcinoma
and prostate cancer cells [38–40]. We also demonstrated
that the apoptosis-inducing activity of NSAIDs is
associated with culture conditions, and cells main-
tained in low serum situation are more sensitive to
NSAIDs [41]. The main targets of NSAIDs to trigger
apoptosis include the bcl-2 gene family, survivin,
Mcl-1, caspases and some upstream mediators like
ceramide and AKT kinase [42–44].
Repression of angiogenesis
The most potent angiogenic growth factor is vascular
endothelial cell growth factor (VEGF). Overexpression
of COX-2 increases the production of eicosanoids like
prostaglandins and thromboxanes, which may induce
VEGF expression and promote tumor angiogenesis
[45,46]. Therefore, it is not surprising that inhibition
of COX-2 activity by celecoxib reduced angiogenesis
and tumor growth in vivo [47]. Interestingly, COX-2
inhibitors may also act via COX-2-independent tar-
gets to attenuate VEGF expression and angiogenesis
[48–50].
MOLECULAR MECHANISMS UNDERLYING
ANTIMETASTATIC ACTION OF NSAIDS
Metastasis is the process by which tumors in situ invade
the surrounding tissues and disseminate to distant
organs via the blood or lymphoid system. This process
involves the acquisition of cell motility, novel cell adhe-
sion properties, and extracellular protease activity.
Therefore, a tumor cell requires: (1) increased migra-
tion caused by reorganization in the cytoskeleton; (2)
a loss of cell-cell adhesion along with a gain of cell-
matrix interaction; and (3) increased expression and
activity of extracellular proteases to degrade the extra-
cellular matrix to allow cell migration and invasion.
Matrix metalloproteinases (MMPs), a family of zinc-
dependent endopeptidases that selectively degrade
components of the extracellular matrix, are involved
not only in tissue remodeling but also in tumor angio-
genesis and metastasis [51]. The MMP family consists
of at least 23 enzymes and may be subgrouped into
different types including collagenases, stromelysins,
gelatinases, matrilysin, membrane-type MMPs, and
metalloelastase, based on substrate specificity and
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sequence characteristics [52,53]. MMPs are synthesized
as inactive precursors and are activated by proteo-
lytic cleavage. Thus, MMP activity can be regulated
at three steps: (1) gene expression; (2) proenzyme
activation; and (3) direct inhibition of enzymatic
activity. The inhibition of MMPs by NSAIDs was first
reported by Abiru et al and our group [54,55]. Abiru
et al demonstrated that aspirin and NS398 suppressed
MMP-9 expression and activity and reduced hepato-
cyte growth factor-induced invasiveness of human
hepatoma cells. In addition, they found that inhibi-
tion of MMP-9 by NSAIDs was associated with the
repression of extracellular signal-regulated kinases
(ERKs). We similarly found that NS398 attenuated
MMP-2 expression in human lung cancer cells [55].
Interestingly, we also found that NS398 inhibited ERK
activation and then repressed Sp1-mediated tran-
scription of MMP-2. These studies suggest that ERKs
are critical targets for NSAIDs to suppress the expres-
sion of different MMPs to reduce the invasive ability
of cancer cells.
Our subsequent study elucidated the molecular
mechanism of NSAID-induced inhibition of ERKs.
We found that NS398 directly interfered with the
recruitment of Raf kinase, an upstream ERK activat-
ing kinase, by membrane-bound Ras protein, there-
fore attenuating growth factor-induced ERK activity
[56]. Moreover, we found that NSAIDs may increase
the expression of MAP kinase phosphatases to induce
dephosphorylation and inactivation of ERKs. In addi-
tion to regulating MMPs, NSAIDs also modulate the
expression and activity of MMP inhibitors. Several
proteins have been shown to exhibit potent inhibitory
activity against MMPs. These include tissue inhibitors
of metalloproteinase (TIMPs), domains of netrins, the
procollagen C-terminal proteinase enhancer (PCPE),
tissue factor pathway inhibitor (TFPI-2), and the newly
identified RECK [57–60]. Our recent study demon-
strated that NSAIDs may upregulate RECK and TIMP-
2 expression in human lung cancer cells to attenuate
tumor-associated MMP activity and invasion [61,62].
Taken together, MMPs and their inhibitors are critical
targets for NSAIDs to repress tumor invasion and
metastasis.
Another class of proteins involved in NSAID-
mediated inhibition of metastasis is matricellular
proteins. These proteins, including secreted protein
acidic and rich in cysteine (SPARC), thrombospondins
(TSPs), osteopontin, Cyr61 and connective growth
factor (CTGF), are secreted proteins that may interact
with the extracellular matrix, cell surface receptors,
growth factors and proteases [63]. Functional studies
suggest that matricellular proteins exhibit multiple
biological activities in the regulation of cell prolifera-
tion, apoptosis, angiogenesis, and tissue remodeling.
Among these members, SPARC and TSPs have been
shown to exert antiangiogenic and antimetastatic
functions. A pioneer work demonstrates that TSP-1 is
upregulated via transcriptional activation by COX-2
inhibitors [64]. Our recent study confirms this result
and indicates that SPARC and TSP-3 are also increased
by NSAIDs [62]. More importantly, we found that
NSAIDs activate SPARC expression via a unique
mechanism, promoter demethylation [62]. Epigenetic
silencing by DNA methylation of tumor suppressor
genes (like SPARC and TSPs) is a general event found
in cancer cells [65]. Promoter methylation is catalyzed
by DNA methyltranferases (DNMTs), which are fre-
quently increased in cancer cells. We demonstrated for
the first time that NSAIDs may suppress the expres-
sion of DNMTs, which leads to demethylation of the
SPARC promoter and reactivation of SPARC expression
in human lung cancer cells [62]. These results suggest
that NSAIDs function as a new class of demethylating
drugs and may be useful in epigenetic therapy.
Although a number of targets that mediate the
antimetastatic action of NSAIDs have been identified,
the list is still increasing. For example, our unpub-
lished results indicate that NSAIDs may also control
the expression of cell adhesion molecules to affect the
migration and invasion of cancer cells. Identification
of all targets may give us a whole picture of NSAID-
induced inhibition of metastasis and provide more
strategies for cancer treatment.
REFERENCES
1. Waddell WR, Loughry RW. Sulindac for polyposis of
the colon. J Surg Oncol 1983;24:83–7.
2. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use
and reduced risk of fatal colon cancer. N Engl J Med
1991;325:1593–6.
3. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, 
a selective cyclooxygenase-2 inhibitor, enhances the
response to preoperative paclitaxel and carboplatin in
early-stage non-small-cell lung cancer. J Clin Oncol
2003;21:2645–50.
4. Crane CH, Mason K, Janjan NA, et al. Initial experi-
ence combining cyclooxygenase-2 inhibition with 
Anti-metastatic action of NSAIDs
Kaohsiung J Med Sci August 2008 • Vol 24 • No 8 395
chemoradiation for locally advanced pancreatic cancer.
Am J Clin Oncol 2003;26:S81–4.
5. Konturek PC, Konturek SJ, Bielanski W, et al. Influence
of COX-2 inhibition by rofecoxib on serum and tumor
progastrin and gastrin levels and expression of
PPARgamma and apoptosis-related proteins in gastric
cancer patients. Dig Dis Sci 2003;48:2005–17.
6. Pruthi RS, Derksen JE, Moore D. A pilot study of use of
the cyclooxygenase-2 inhibitor celecoxib in recurrent
prostate cancer after definitive radiation therapy or
radical prostatectomy. BJU Int 2004;93:275–8.
7. Vane JR. Inhibition of prostaglandin synthesis as a
mechanism of action for aspirin-like drugs. Nat New
Biol 1971;231:232–5.
8. Griswold DE, Adams JL. Constitutive cyclooxygenase
(COX-1) and inducible cyclooxygenase (COX-2): ratio-
nale for selective inhibition and progress to date. Med
Res Rev 1996;16:181–206.
9. Wu KK. Biochemical pharmacology of nonsteroidal
anti-inflammatory drugs. Biochem Pharmacol 1998;55:
543–7.
10. Dubois RN, Abramson SB, Crofford L, et al. Cyclo-
oxygenase in biology and disease. FASEB J 1998;12:
1063–73.
11. Simmons DL, Botting RM, Hla T. Cyclooxygenase
isozymes: the biology of prostaglandin synthesis and
inhibition. Pharmacol Rev 2004;56:387–437.
12. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation
of cyclooxygenase 2 gene expression in human colorec-
tal adenomas and adenocarcinomas. Gastroenterology
1994;107:1183–8.
13. Hwang D, Scollard D, Byrne J, et al. Expression of
cyclooxygenase-1 and cyclooxygenase-2 in human breast
cancer. J Natl Cancer Inst 1998;90:455–60.
14. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression
of cyclooxygenase-2 in carcinoma of the pancreas. Clin
Cancer Res 1999;5:2018–24.
15. Tucker ON, Dannenberg AJ, Yang EK, et al.
Cyclooxygenase-2 expression is up-regulated in human
pancreatic cancer. Cancer Res 1999;59:987–90.
16. Hida T, Yatabe Y, Achiwa H, et al. Increased expression
of cyclooxygenase 2 occurs frequently in human lung
cancers, specifically in adenocarcinomas. Cancer Res
1998;58:3761–4.
17. Cohen EG, Almahmeed T, Du B, et al. Microsomal
prostaglandin E synthase-1 is overexpressed in head
and neck squamous cell carcinoma. Clin Cancer Res
2003;9:3425–30.
18. Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2
transactivates EGF receptor: a novel mechanism for
promoting colon cancer growth and gastrointestinal
hypertrophy. Nat Med 2002;8:289–93.
19. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of
prostaglandin E receptor subtype EP(4) in colon carcino-
genesis. Cancer Res 2002;62:28–32.
20. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase 
regulates angiogenesis induced by colon cancer cells.
Cell 1998;93:705–16.
21. Gately S. The contributions of cyclooxygenase-2 to
tumor angiogenesis. Cancer Metastasis Rev 2000;19:19–27.
22. Lin MT, Lee RC, Yang PC, et al. Cyclooxygenase-2
inducing Mcl-1-dependent survival mechanism in hu-
man lung adenocarcinoma CL1.0 cells. Involvement of
phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem
2001;276:48997–9002.
23. Sorokin A. Cyclooxygenase-2: potential role in regula-
tion of drug efflux and multidrug resistance phenotype.
Curr Pharm Des 2004;10:647–57.
24. Huang M, Sharma S, Mao JT, et al. Non-small cell lung
cancer-derived soluble mediators and prostaglandin
E2 enhance peripheral blood lymphocyte IL-10 tran-
scription and protein production. J Immunol 1996;157:
5512–20.
25. Dermond O, Ruegg C. Inhibition of tumor angiogenesis
by non-steroidal anti-inflammatory drugs: emerging
mechanisms and therapeutic perspectives. Drug Resist
Updat 2001;4:314–21.
26. Costa C, Soares R, Reis-Filho JS, et al. Cyclooxygenase 2
expression is associated with angiogenesis and lymph
node metastasis in human breast cancer. J Clin Pathol
2002;55:429–34.
27. Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-
2 (COX-2)-independent anticarcinogenic effects of
selective COX-2 inhibitors. J Natl Cancer Inst 2006;98:
736–47.
28. Cha YI, DuBois RN. NSAIDs and cancer prevention:
targets downstream of COX-2. Annu Rev Med 2007;
58:239–52.
29. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxyge-
nases in angiogenesis. Curr Med Chem 2000;7:1163–70.
30. Rao CV, Reddy BS. NSAIDs and chemoprevention.
Curr Cancer Drug Targets 2004;4:29–42.
31. Kardosh A, Blumenthal M, Wang WJ, et al. Differential
effects of selective COX-2 inhibitors on cell cycle regu-
lation and proliferation of glioblastoma cell lines. Cancer
Biol Ther 2004;3:55–62.
32. Narayanan BA, Condon MS, Bosland MC, et al.
Suppression of N-methyl-N-nitrosourea/testosterone-
induced rat prostate cancer growth by celecoxib: effects
on cyclooxygenase-2, cell cycle regulation, and apoptosis
mechanism(s). Clin Cancer Res 2003;9:3503–13.
33. Grosch S, Tegeder I, Niederberger E, et al. COX-2 
independent induction of cell cycle arrest and apoptosis
in colon cancer cells by the selective COX-2 inhibitor
celecoxib. FASEB J 2001;15:2742–4.
34. Maier TJ, Schilling K, Schmidt R, et al. Cyclooxygenase-
2 (COX-2)-dependent and -independent anticarcino-
genic effects of celecoxib in human colon carcinoma
cells. Biochem Pharmacol 2004;67:1469–78.
35. Hung WC, Chang HC, Pan MR, et al. Induction of
p27(KIP1) as a mechanism underlying NS398-induced
growth inhibition in human lung cancer cells. Mol
Pharmacol 2000;58:1398–403.
36. Huang YC, Chuang LY, Hung WC. Mechanisms under-
lying nonsteroidal anti-inflammatory drug-induced
p27(Kip1) expression. Mol Pharmacol 2002;62:1515–21.
Kaohsiung J Med Sci August 2008 • Vol 24 • No 8396
W.C. Hung
37. Waskewich C, Blumenthal RD, Li H, et al. Celecoxib
exhibits the greatest potency amongst cyclooxygenase
(COX) inhibitors for growth inhibition of COX-2-
negative hematopoietic and epithelial cell lines. Cancer
Res 2002;62:2029–33.
38. Nam DH, Park K, Park C, et al. Intracranial inhibition
of glioma cell growth by cyclooxygenase-2 inhibitor
celecoxib. Oncol Rep 2004;11:263–8.
39. Wun T, McKnight H, Tuscano JM. Increased 
cyclooxygenase-2 (COX-2): a potential role in the patho-
genesis of lymphoma. Leuk Res 2004;28:179–90.
40. Dandekar DS, Lopez M, Carey RI, et al. Cyclooxygenase-
2 inhibitor celecoxib augments chemotherapeutic drug-
induced apoptosis by enhancing activation of caspase-3
and -9 in prostate cancer cells. Int J Cancer 2005;115:
484–92.
41. Chang HC, Weng CF. Cyclooxygenase-2 level and cul-
ture conditions influence NS398-induced apoptosis and
caspase activation in lung cancer cells. Oncol Rep 2001;
8:1321–5.
42. Jazirehi AR, Bonavida B. Resveratrol modifies the
expression of apoptotic regulatory proteins and sensi-
tizes non-Hodgkin’s lymphoma and multiple myeloma
cell lines to paclitaxel-induced apoptosis. Mol Cancer
Ther 2004;3:71–84.
43. Kern MA, Schubert D, Sahi D, et al. Proapoptotic and
antiproliferative potential of selective cyclooxygenase-
2 inhibitors in human liver tumor cells. Hepatology
2002;36:885–94.
44. Kundu N, Smyth MJ, Samsel L, et al. Cyclooxygenase
inhibitors block cell growth, increase ceramide and
inhibit cell cycle. Breast Cancer Res Treat 2002;76:57–64.
45. Li G, Yang T, Yan J. Cyclooxygenase-2 increased the
angiogenic and metastatic potential of tumor cells.
Biochem Biophys Res Commun 2002;299:886–90.
46. Liu XH, Kirschenbaum A, Yao S, et al. Upregulation of
vascular endothelial growth factor by cobalt chloride-
simulated hypoxia is mediated by persistent induction
of cyclooxygenase-2 in a metastatic human prostate
cancer cell line. Clin Exp Metastasis 1999;17:687–94.
47. Gately S, Li WW. Multiple roles of COX-2 in tumor
angiogenesis: a target for antiangiogenic therapy. Semin
Oncol 2004;31:2–11.
48. Ostrowski J, Wocial T, Skurzak H, et al. Do altering 
in ornithine decarboxylase activity and gene expres-
sion contribute to antiproliferative properties of COX
inhibitors? Br J Cancer 2003;88:1143–51.
49. Thyss R, Virolle V, Imbert V, et al. NF-kappaB/Egr-1/
Gadd45 are sequentially activated upon UVB irradia-
tion to mediate epidermal cell death. EMBO J 2005;24:
128–37.
50. Thiel G, Cibelli G. Regulation of life and death by the
zinc finger transcription factor Egr-1. J Cell Physiol
2002;193:287–92.
51. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix
metalloproteinases and tumor invasion: from correla-
tion and causality to the clinic. Semin Cancer Biol 1996;
7:147–54.
52. Pupa SM, Ménard S, Forti S, et al. New insights into
the role of extracellular matrix during tumor onset and
progression. J Cell Physiol 2002;192:259–67.
53. Giannelli G, Falk-Marzillier J, Schiraldi O, et al.
Induction of cell migration by matrix metalloprotease-
2 cleavage of laminin-5. Science 1997;277:225–8.
54. Abiru S, Nakao K, Ichikawa T, et al. Aspirin and NS-398
inhibit hepatocyte growth factor-induced invasiveness
of human hepatoma cells. Hepatology 2002;35:1117–24.
55. Pan MR, Hung WC. Nonsteroidal anti-inflammatory
drugs inhibit matrix metalloproteinase-2 via suppres-
sion of the ERK/Sp1-mediated transcription. J Biol Chem
2002;277:32775–80.
56. Pan MR, Chang HC, Hung WC. Non-steroidal anti-
inflammatory drugs suppress the ERK signaling path-
way via block of Ras/c-Raf interaction and activation of
MAP kinase phosphatases. Cell Signal 2008;20:1134–41.
57. Banyai L, Patthy L. The NTR module: domains of
netrins, secreted frizzled related proteins, and type I pro-
collagen C-proteinase enhancer protein are homologous
with tissue inhibitors of metalloproteases. Protein Sci
1999;8:1636–42.
58. Egeblad M, Werb Z. New functions for the matrix 
metalloproteinases in cancer progression. Nat Rev Cancer
2002;2:161–74.
59. Stetler-Stevenson M, Mansoor A, Lim M, et al. Expression
of matrix metalloproteinases and tissue inhibitors of
metalloproteinases in reactive and neoplastic lymphoid
cells. Blood 1997;89:1708–15.
60. Takahashi C, Sheng Z, Horan TP, et al. Regulation of
matrix metalloproteinase-9 and inhibition of tumor
invasion by the membrane-anchored glycoprotein RECK.
Proc Natl Acad Sci USA 1998;95:13221–6.
61. Liu LT, Chang HC, Chiang LC, et al. Induction of
RECK by nonsteroidal anti-inflammatory drugs in lung
cancer cells. Oncogene 2002;21:8347–50.
62. Pan MR, Chang HC, Chuang LY, et al. The nonsteroidal
anti-inflammatory drug NS398 reactivates SPARC
expression via promoter demethylation to attenuate
invasiveness of lung cancer cells. Exp Biol Med 2008;
233:456–62.
63. Framson PE, Sage EH. SPARC and tumor growth:
where the seed meets the soil? J Cell Biochem 2004;92:
679–90.
64. Moon Y, Bottone FG Jr, McEntee MF, et al. Suppression
of tumor cell invasion by cyclooxygenase inhibitors is
mediated by thrombospondin-1 via the early growth
response gene Egr-1. Mol Cancer Ther 2005;4:1551–8.
65. Esteller M. Epigenetic gene silencing in cancer: the
DNA hypermethylome. Hum Mol Genet 2007;16:R50–9.
Kaohsiung J Med Sci August 2008 • Vol 24 • No 8 397
收文日期：97 年 8 月 20 日
接受刊載：97 年 8 月 30 日
通訊作者：洪文俊教授
國立中山大學生物醫學研究所
高雄市 804蓮海路七十號
流行病學研究顯示非類固醇抗發炎藥物可降低數種癌症的罹患率及死亡率；然而，非
類固醇抗發炎藥物如何發揮其化學預防與抗癌作用之分子機制尚未清楚。第一及第二
型環氧化酶是非類固醇抗發炎藥物主要之標靶；最近研究發現第二型環氧化酶在許多
腫瘤組織均會過度表現，同時可經由 (1) 刺激癌細胞增生，(2) 增加腫瘤血管新生，
(3) 降低癌細胞凋亡，(4) 調節免疫反應及 (5) 增進癌症轉移以促使腫瘤生成。可預期
的，非類固醇抗發炎藥物可能藉由抑制這些步驟以減少癌症發生。在此綜論，我們討
論非類固醇抗發炎藥物之抗癌機制，尤其深入闡釋這些藥物如何抑制癌症轉移。
非類固醇抗發炎藥物之抗腫瘤轉移作用
洪文俊
國立中山大學  生物醫學研究所
關鍵詞：癌症，轉移，非類固醇抗發炎藥物，腫瘤形成
(高雄醫誌 2008;24:392–7)
